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I.	  Executive	  Summary	  
The most common type of brain tumor is the glioma and despite advances in diagnostic 
imaging and drug delivery, there are no effective cures.  This is due to the malignant glioma’s 
tendency to recur after treatment, with the recurrence being within a 4cm region from the edge at 
which it was surgically removed.  However, local delivery mechanisms have provided a way for 
drug to reach the malignant tumors directly. One of these mechanisms is the use of the drug 
BCNU that is inserted into the cavity via dissolvable Gliadel wafers. These wafers have shown 
the ability to provide high drug concentrations to a localized area, but at a limited penetration 
distance of 1 to 2 cm.  Consequently, our objective is to improve the design of the Gliadel wafer 
by encapsulating the BCNU in nanoparticles consisting of PSA with the goal that these 
nanoparticles will diffuse far enough from the wafers that the drug will reach a higher 
penetration distance.  
The drug delivery was modeled in COMSOL, using three governing equations: one to 
model the diffusion of the nanoparticles from the wafer into the tissue, one to model the 
diffusion of the drug out of the nanoparticles into the tissue, and another to model interstitial 
fluid flow in the brain. An axisymmetric cylindrical geometry was used to model the entire 
complex. The concentration of the BCNU out of the nanoparticles was modeled proportionally to 
the volume of the nanoparticle that was degraded. To accurately model drug delivery, interstitial 
fluid flow was taken into account due to its ability to cause a significant convective flux for the 
transport of macromolecules.   
The simulation was run for 12 days and a distance of 4cm from the removed tumor was 
reached above the therapeutic value of 5.394 x 10-12 mg/mm3.  This was then compared to the 
method of BCNU delivery directly from the Gliadel wafers which are in the absence of 
nanoparticles. The results show that upon reaching the threshold value, the wafer containing 
nanoparticles diffused further into the brain tissue in comparison to the Gliadel wafer merely 
containing BCNU. Not only this, but the BCNU was also able to maintain at therapeutic levels 
for over 24 hours at the goal distance of 4cm from the tumor site.   
The ability of BCNU to reach a distance of 4cm from the tumor site supports the success 
of our design. This result strongly suggests that this method of drug delivery may treat the 
malignant glioma more successfully when compared to alternative cancer treatments. Design 
recommendations to more accurately model this process include adjustments to the geometry, 
nanoparticle diffusion and degradation, and assumptions made within the cavity region.   
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II.	  Introduction	  
A glioma is the most common type of brain cancer.  It forms in the glial or supportive 
tissue in the brain and is a primary brain cancer, meaning that it develops from cells that 
originate within the brain.  One such kind of glioma is an astryocytoma which forms from small 
star shaped cells called astrocytes.  An astryocytoma can occur anywhere within the brain or 
even spinal cord. It occurs most often in adult cerebrum tissue.  Astryocytomas are graded 
according to the severity of the tumor. A grade IV astryocytoma is called a glioblastoma 
multiforme and is categorized by aggressive growth and speed [22]. They account for more than 
50% of all astryocytoma cases.  Glioblastoma multiforme is also known to recur after surgical 
removal of the tumor within the 2-4cm radius past the edge of the original lesion [12].Symptoms 
of gliomas, which may slowly appear at first, include headaches, seizures, personality changes, 
weakness in arms or legs, and numbness.  The intensity of symptoms may vary; and some 
patients may be diagnosed only after coming in for a totally different issue. The typical life 
expectancy is 6 to 24 months after initial diagnosis [23].  
Surgery is the most common treatment method, with the biopsy being a key step in 
diagnosis.  Surgery is used to remove as much of the tumor as possible, and the biopsied tissue is 
used to determine the tumor composition.  The biopsy results determine which treatment is best 
[12].  There are two adjuvant treatments for tumors after surgery: radiation and chemotherapy. 
However, most cancerous glioma cells are partially resistant to chemotherapy and radiation 
[11].  Radiation therapy is used to treat high grade gliomas and recurrent gliomas. Two types of 
radiation therapy include stereotactic radiation (SRS) and brachytherapy. However, SRS is often 
not used due to an increased chance of radiation-induced toxicity. Brachytherapy’s application is 
limited as well because it can only be applied to about 20% of brain tumors and can induce 
complications of homonymous quadrantanopia, focal necrosis, edema, and neurological 
disorientation [12]. Chemotherapy, including localized therapy, is sometimes used in 
combination with radiation after surgery. Currently, chemotherapy alone is the most common 
treatment. 
One such chemotherapeutic method being used is the implantation of Gliadel wafer into 
the excised tumor cavity created post-surgery. Though a promising method, improving the 
diffusion of the release of drug can further improve this method.  Gliadel wafers contain the drug 
Carmustine, or BCNU.  BCNU is a cell cycle nonspecific akylating agent, affecting cells most 
when in their resting stage.  BCNU attacks tissue by damaging the RNA and DNA responsible 
for proliferation which causes the cells to die or induce apoptosis because they can no longer 
divide. [5]  
We will be working off the methodology from Gliadel to create an implantable localized 
treatment method that has BCNU incorporated into the wafer within spherical nanoparticles. The 
nanoparticles are present in the bulk of the wafer and are evenly dispersed.  A polymer is being 
used in the hopes of protecting the drug from degradation as it diffuses, therefore allowing it to 
reach further into the tissue.  The PSA nanoparticles will degrade via surface erosion.  This will 
allow for a constant release of drug that is proportional to the amount of volume degraded of the 
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nanoparticle.  By inserting these wafers directly into the tissue, they provide a sustained local 
chemotherapy at the site of the tumor. The total amount of BCNU within these nanoparticles will 
be equal to the total amount of BCNU within the Gliadel wafers to make a more accurate 
comparison of the methods. This is so that it better targets all the remaining cancerous, gliomal 
tissue with the toxic dose, while keeping a concentration low enough in the healthy tissues 
outside the 2-4 cm radius to protect them from apoptosis. For the current methods in use, BCNU 
does not reach this distance required to prevent recurrence.  Reaching a 4cm distance into the 
tumorous tissue could potentially kill 98% of the remaining cancerous cells [10]. Making this 
possible during actually surgical operations could significantly reduce the mortality rate of this 
deadly disease. 
	  
IIA.	  Design	  Objectives:	  
Using COMSOL, we will model the release of spherical nanoparticles from the wafer and 
the release of drug, BCNU, from the nanoparticles as they degrade with time. We will do this in 
order to: 
1) Determine how BCNU diffuses through the brain from the wafer with time  
2) Determine how far into the normal tissue BCNU is able to diffuse using this delivery 
method 
3) Compare the nanoparticle delivery method with current delivery method used by 
Gliadel 
 
IIB.	  Problem	  Schematic:	  	  
In COMSOL, we used a 2D axisymmetric cylindrical model containing the tumor cavity 
where the tumor was removed, remaining tumor after surgery layer, wafer layer, and normal 
tissue domain. The cavity, tumor layer, and wafers were modeled as hemispheres with respective 
thicknesses of 14.5mm, 3.1 mm and 1mm. The normal tissue was modeled just beyond the tumor 
layer, covering a 10cm region. The nanoparticles were initially embedded within the wafers and 
encapsulate the drug, BCNU. The nanoparticles are made of PSA, known as poly(sebacic acid), 
whose molecules are linked together by anhydride bonds.  These bonds split over time due to 
hydrolysis, which cause surface erosion to take place and BCNU to be released [12]. Both the 
diffusion of the nanoparticles from the wafers and the radial diffusion of BCNU from the 
nanoparticle were modeled.  There is no BCNU present in any of the domains prior to release of 
the nanoparticles.  BCNU modeled to be generated as a function of the concentration of BCNU 
per volume of nanoparticles, the concentration of nanoparticles, and the change in volume of the 
nanoparticles with respect to time.  BCNU is released to diffuse and will degrade by first order 
kinetics.  Further diffusion of BCNU into the normal tissue is anticipated due to its encapsulation 
within the nanoparticles, which protect the drug from degradation.   
Convection was taken into account through the modeling of the interstitial fluid flow in 
each area of the brain based on the unique physical properties of the cavity, wafers, tumor layer, 
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and into the normal tissue.  The fluid flow to the area is due to fluid being brought to the area by 
the vascular tissues.  There is increased flow to the area following surgery as the body tries to 
heal itself, which causes pressure to build up in these vessels and fluid to leak out.  Instead of 
modeling the complex vascular network present in the brain tissue, our model assumes a fluid 
generation term that models the increased fluid to the region. The schematic of the model is 
shown in Figure 1 below.   
 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	    
Figure 1: Schematic of 2D axisymmetric cylindrical model.  The figure shows the cavity, wafer layer, tumor layer and normal tissue, as 
respectively labeled.  The cavity is 14.5 mm radially, the wafers at 1.0 mm, and the remaining tumor layer left after surgery is 3.1mm.  The rest of 
the domain extends to 100 mm and is considered to the normal brain tissue.  The circles represent the nanoparticles outwardly diffusing from the 
wafers and the arrows next to the circles show the direction this diffusion.  Further arrows describe the fluid flow, which is the same direction as 
diffusion.  The boundaries of the domain are labeled with the boundary conditions used in the simulation.  The right of the figure shows a zoomed 
in version of the nanoparticle.  This close up shows a solid line around the edge of the nanoparticle showing the outline of the nanoparticle before 
volume was released and the dotted line shows the edge of the nanoparticle at a later time after surface erosion has taken place. The arrows 
pointing outward represent the BCNU release through surface erosion and the direction of diffusion. 
   
 Figure 1 shows the diffusion of nanoparticle from the wafer layer and through the tumor 
layer and into the normal tissue.  Additionally, it displays the interstitial fluid flow in the brain as 
well as the boundary conditions applied to the overall 2D cylindrical model.  The nanoparticles 
are shown more precisely on the right hand side of figure 1.  The close up of the nanoparticle 
shows the release of BCNU from the nanoparticles, as well as how the volume of the 
nanoparticle decreases with time due to this release.   
III.	  Results	  
To determine how the BCNU moved throughout the tumor layer and into the normal 
tissue, our model was run for 12 days.  Over this time period, the impacts on the concentration 
profile both during the edema at maximum value and as the edema decreased were observed. 
Initially, the BCNU diffuses out the wafer symmetrically.  There is a high concentration 
of BCNU closest to the wafer and a lower concentration of BCNU at an increased distance from 
the wafer layer.  The symmetrical surface plot displaying the initial BCNU diffusion is 
represented by Figure 2 below. 
7	  
	  
 
Figure 2: Surface Plot of Concentration of the Initial Diffusion of BCNU.  The figure shows the concentration surface plot of BCNU 
at time = 16 hours.  The colors on this plot represent different concentrations of BCNU in mg/mm3 of tissue with the scale on the right of the 
figure.  The red shows higher concentrations whereas the blue shows lower concentrations.  The drug is only diffusing at this time point within 
the simulation because the edema is a maximum values, causing the only physics to be the simple diffusion of the drug.  This creates a 
symmetrical drug diffusion pattern that is progressing radially away from the wafer layer in both directions.   
This pattern of drug concentration modeled in Figure 2 occurs because the edema is at 
maximum values at this initial time period.  Because the edema slows the velocity within the 
tissue, the nanoparticles and drug are only able to travel via simple diffusion, and therefore 
diffuse symmetrically.  More about this is phenomenon is explained within the Edema section of 
the Sensitivity Analysis.  
As the edema decreases and the excess fluid is released from the area, the pressure 
gradient reforms, and the bulk flow of fluid becomes significant again.  This is shown in Figure 3 
below which displays the concentration profile of our model after 12 days.    
  
Figure 3: BCNU concentration profile at day 12.  The concentrations of BCNU are not uniformly distributed radially and are greatest 
at the top of the normal tissue.  The velocity is smallest at the top boundary because of an assumed no-slip condition.  The velocity is also 
smallest further from the wafer because the pressure gradient is less significant at further radial distances. This causes a deposition of drug within 
the area closest to the top boundary and furthest from the wafer.   
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As seen in Figure 3, the decrease of the edema causes a shift from a symmetric to a non-
symmetric diffusion pattern.  This non-symmetrical nature of the drug is due to the no slip 
boundary condition assumed at the top of our geometry, which causes the fluid velocity to be 
slower in the areas surrounding this region.  The velocity is also smaller the further from the 
wafer because the pressure gradient is less significant.  Since the fluid velocity decreases, the 
drug is able to collect, and there will be higher concentrations present in this region compared to 
distances further away from the top boundary and/or closer to the wafer.  Further distances from 
the top boundary have a greater continuous bulk flow and will thus have lower concentrations of 
drug. 
Interestingly, even with the non-symmetrical concentration profile at the end of the 
simulation, the maximum penetration distance reached by the drug is the same at all radial points 
along the progressing drug front.  The maximum penetration distance of the drug was considered 
to be the maximum distance from the edge of the removed tumor where the optimization 
function would reach zero at day 11.  The characteristic curve seen at these distances is shown in 
Figure 32 in Appendix D.  Figure 4 shows that the furthest radial distances from the wafer have 
very low values for velocity magnitude.  This causes diffusion to be the main method of transfer 
for the BCNU at these distances. 
 
Figure 4: Contour Plot of Velocity in the Brain.  The area closest to the top boundary has very low velocities due to the no slip 
boundary assumed there.  The velocity contours are highest and most concentrated in the area by the wafer and tumorous tissue due to the high-
pressure gradient presence there.  The high-pressure gradient there causes more convective flow in that region.  As distance increases radially 
from the wafer layer, the velocity decreases quite a bit, and isn’t as significant as the velocities experienced closer to the wafers.   
Because the drug front is already at a far enough distance as the edema decreases, the 
convective effects are not experienced by the front.  Thus, diffusion of drug along the front 
continues symmetrically due to the lack of convective effects.  The main pressure gradient, and 
hence velocity gradient, is formed in the area closest to the wafer layer, but as distance from the 
wafer increases, the velocity effects become less and less significant.  This means that the 
penetration distance is symmetrical. 
Therapeutic levels of BCNU reached to over the 4 cm point within the normal tissue.  In 
order to be effective, the BCNU must be at the threshold value of 5.394x10-12 mg/mm3 of tissue 
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for at a minimum of 24 hours.  Because Gliadel wafers produced therapeutic levels of BCNU for 
24 hours at the distances reached, we were concerned with having our method create a drug 
presence for 24 hours.  Even though the therapeutic drug concentration presence was only 
required to be 2 hours due to in vitro studies, we looked to have the therapeutic concentration of 
drug for 24 hours to make a better comparison to Gliadel’s effect.  The drug reached this desired 
concentration at our goal distance of 4cm from the edge of the removed tumor.  This is shown in 
the Figure 5 below.   
 
Figure 5: BCNU Concentration at 4cm from Removed Tumor.  The concentration profile in the figure is taken at a distance of 4cm 
radially away from the edge of the tumor.  The BCNU concentration reaches therapeutic values (5.394 x 10-12 mg/mm3 of tissue) and rises well 
above it, with a maximum magnitude on the order of 10-5mg/mm3 tissue.  The concentration peaks around 11 days. 
Figure 5 shows that the BCNU concentration reaches well above 5.394 x 10-12 mg/mm3 
of tissue and remains at this concentration for well over 24 hours.  Figure 6 below displays the 
optimization graph of the concentration of drug with increased distance from the cavity/tumor 
layer interface over 12 days.  The optimization equation was considering the positive factor of 
having the drug at therapeutic levels, and negative factor of having the drug at toxic levels or 
below therapeutic levels.  Concentrations below therapeutic levels occurred before the lines 
reached zero, and zero marked the point where the therapeutic value was reached.  A spike 
following zero concentration would indicate toxic levels, or the drug degrading back to below 
therapeutic levels.   
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Figure 6: Optimization Function for the Concentration of BCNU into Normal Tissue for 12 days at various distances.  The 
optimization function used assigned positive values equal to the difference between the current concentration and therapeutic levels.  If a 
concentration was at or above therapeutic levels while below toxic levels, the optimization function assigns that point a value of zero.  The drug 
reaches therapeutic levels of BCNU at around day 3 at the 4 cm goal point.  The drug is able to reach an ultimate penetration distance of 5.74 cm 
from the edge of the removed tumor.  This is well above the distance reached by the current Gliadel method.   
In Figure 6 it can be seen that at a distance of 4cm from the edge of the removed tumor, 
the optimization value reached zero, indicating that therapeutic concentrations were reached at 
this distance, around day 3.  The drug remained at therapeutic levels for all distances less than 4 
cm for majority of the 12 days of the simulation.  As stated above, the maximum penetration 
distance of the drug was considered to be the maximum distance from the edge of the removed 
tumor where the optimization function would reach zero at day 11.  This would mean that the 
drug was at therapeutic levels for a day of our simulation, which was comparable to the current 
method of treatment that has therapeutic levels of BCNU for approximately a day.  The 
maximum distance reached in this model was 5.74 cm.  The true penetration distance may be 
even further than that, but our simulation is limited by the time it was run.  If the model were run 
longer, the true penetration distance would be the maximum distance from the edge of the tumor 
where therapeutic concentrations of BCNU were reached for a minimum of one day.  Because 
the simulation was only run for 12 days, there may be a distance where therapeutic levels of 
BCNU were reached at a day past day 12 and were present above that level for a day.    
As mentioned above, Gliadel wafers are the current method of treatment.  Clinical trials 
have shown that therapeutic levels of BCNU are reached at a limited distance from the wafer.  
Most papers cite a penetration distance of a mere 1-2cm from the edge of the resurrected tumor, 
and the drug is only present at this distance for approximately 24 hours.  This indicates that this 
treatment method needs to be improved.  Our model has shown the ability to achieve the 
distances reached by the current delivery method and far succeed them.  Encapsulating the 
BCNU within nanoparticles, allows for the drug to therapeutically treat the cells up to 5.74 cm 
from the edge of the tumor resection cavity, and can therefore efficiently treat a much larger 
region than the current Gliadel wafers are able.  It also provides the cells with a more consistent, 
continuous exposure the to BCNU which can make the anti-proliferative effects of the drug more 
efficient to the larger range of penetration.  This larger treatment zone can lead to less recurrence 
of tumors and hence and increased survival rate for those diagnosed with MGB.   
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IV.	  Mesh	  Convergence	  	  
An analysis of our model’s simulation mesh was done to ensure that our results were as 
accurate as possible to prevent discretization errors.  We were aiming to have our results 
maintain certain accuracy while not having COMSOL perform unnecessary calculations.  The 
concentration of BCNU 2 cm from the wafer within the normal tissues was analyzed at times of 
800,000 and 900,000 seconds.  The mesh spanning the tumor region and the wafer region was 
necessitated to be extremely fine because the highest rates of change occur within these regions.  
Hence, only the numbers of elements in the portion of the mesh outside of the wafer and tumor 
region, and within the cavity and normal tissue domains, were changed.  The mesh was analyzed 
for convergence by changing these portions of the mesh to various predefined meshes.  
When changing the mesh to a size of less than 7702 elements, a computing error would 
occur because the mesh would not converge.  This was due to the fact that there were not enough 
elements to accurately give a solution to the problem.  A custom maximum element sized mesh 
was then used in conjunction with the remaining regions set to the finest predefined mesh 
possible.  The maximum element size was slightly decreased in order to further analyze how 
many elements were needed for an accurate solution. The total number of elements was then 
plotted against the concentration of BCNU at specific times equal to 9.26 and 10.42 days at the 
defined point 2 cm from the wafer within the healthy tissue called ‘2cm into normal tissue’. This 
was used because it was not within the tumor or wafer region whose mesh was already defined 
and was not as far out as our goal point, which may have had many times were the concentration 
was zero. This made analyzing any change in concentration, at this point at a specific time, due 
solely to the change of mesh size easier. The graphs where the concentration values were taken 
at 9.26 and 10.42 days are shown below in Figure 7. 
 
Figure 7: Mesh Convergence of BCNU Concentration at 2 cm into the normal tissue at times 9.26 and 10.42 days verses the number 
of elements.  The mesh appears to converge at 7702 elements due to the concentration varying very little with a very large increase in element 
number. 
The mesh converges and no more significant change in accuracy of the solutions is seen 
after a mesh of 7702 elements, as shown.   In Figure 8, it is shown from the plateau in values that 
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a mesh of 7702 elements is sufficient enough and that more elements than this will not 
significantly increase the accuracy of the solution.  
Figure 8 below shows the final mesh chosen.  The difference in element size between the 
tumor/ wafer region and the remaining tissue is shown by the differences in the element size and 
the density of the elements.  
 
Figure 8: Final mesh for the model.  This mesh consists of 7702 elements, which is the number of elements at which the solution 
converged.  There is a much higher density of elements in the region of the tumor and wafer layers due to this being the region with the highest 
amount of change.  A finer mesh was used within the cavity and outlying normal tissue regions.   
As shown in Figure 8, the difference in element size between the tumor/ wafer region and 
the remaining tissue is evident. It is also clear that the values and shape of the BCNU 
concentration graph at 2cm into the normal tissue does not significantly change at a mesh finer 
than 7702 elements. Though meshes with a larger number of elements give slightly more 
accurate answers, the concentration solution value differences are to the power of 10-5, meaning 
the differences between each mesh’s solution is small enough that the extra calculation time in 
COMSOL would be quite significant in relation to the small amount of added accuracy. Table 1 
in Appendix D shows each trial that was run, under each number of elements, and the solutions 
that were produced.   
V.	  Accuracy	  Check	  
i.	  Pressure	  
Our model included the added complexity of accounting for the interstitial fluid flow 
within the brain that aids in the transport of drug.  We made simplifications of the true process 
and so compared the fluid specific properties of our model to other experimental and simulated 
values.  Figure 9 below shows the pressures associated with each region of the brain within our 
domain. 
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Figure 9: Surface Plot of Pressure in the Brain Excluding the Impacts of the Edema.  The pressure in the cavity and wafer layer are the highest 
(red), followed by the tumor layer (lighter red), and last the model tissue (yellow to blue).  This shows a pressure gradient (high to low) from the 
cavity to the normal tissue. 
Figure 9 shows that the pressure is highest in the cavity, then in the tumor layer, and last 
in the normal tissue.  This pressure gradient accounts for the velocity and direction of fluid flow 
within the brain.   
a)	  Pressure	  in	  Cavity	  
 Figure 25 in Appendix D displays the pressure of our model over a period of 3 days.  
During the first 3 hours our model stayed at the constant pressure of approximately 1,280 Pa.  In 
comparison, Figure 24 in Appendix D shows the pressure values from literature increasing in 
steps over the 3 hour period before reaching the steady-state pressure of 1000 Pa just after 2 
hours.  This increase in pressure is due to the pressure associated with the cavity filling up with 
interstitial fluid.  Because our model assumed that the cavity was already full, there was no 
increase in pressure, but instead began at the steady state condition.  This was an acceptable 
assumption because our 12 day model had a time step of 4 hours, and due to the limits of 
computing time and power, the variance seen in the 3 hours of the literature model would not be 
visible in our model. The steady state values of our model and the literature model are consistent, 
thus verifying our assumption.    
b)	  Pressure	  in	  Tumor	  Layer	  
Figure 27, in Appendix D, shows our model of pressures throughout the tumor layer in 
the first 3 hours is the same as that in the cavity and shows a steady line at 1,280 Pa.  In 
comparison, in Figure 26, in Appendix D, the pressure values from literature show a sharp 
decrease from 1,200 Pa to 500 Pa before 0.5 hours.  This decrease is due to the vast decrease in 
pressure as fluid flows into the cavity.  At this point there is a large pressure difference between 
the cavity and the tumor layer as the interstitial fluid is driven into the cavity from the tumor 
layer.  Pressure is driven to a minimum value at this point and then recovers and again rises in 
steps until a steady-state value of 1000 Pa is reached just after 2 hours.  Again, because our 
model assumed that the cavity was already full, there was no decrease in pressure, but instead 
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began at the steady state condition of pressure.  The steady state values of our model and the 
literature model are consistent, thus verifying our assumption. 
c)	  Pressure	  in	  Normal	  Tissue	  
Figure 29, in Appendix D, shows our model at a steady pressure at 915 Pa in the normal 
tissue during the first 3 hours.  In comparison, in Figure 28 (Appendix D) the pressure values 
from literature encounter a decrease from 900 Pa to 700 Pa before 0.5 hours and then rise in 
steps until they reach a value of 900 Pa.  This is similar to that of the tumor layer in that pressure 
drops within the first 30 minutes as the cavity fills and then rises until it reaches steady-state. In 
the normal tissue, our pressure values are the same at steady-state as those pressure values in the 
literature.    
d)	  Pressure	  Conclusions	  
As explained in the above sections, our pressure values are comparable with those found 
in other simulations in literature. Because of this, the error due to the simplification of having the 
cavity full and pressures at steady state initially is limited.  
ii.	  Velocity	  	  
Figure 10 below shows the interstitial fluid flow within the brain.  The arrows show the 
direction of the velocity but are not to scale of the magnitude of the velocity at each point.  
 
Figure 10: Arrows Showing Velocity Direction in the Brain.  The high pressure in the cavity and the lower pressure present in the 
normal tissue creates a pressure gradient.  This pressure gradient causes a direction of flow down the pressure concentration gradient.  This is 
seen in the figure by the arrows point in the direction from the wafer boundary to the outflow boundaries on the right and bottom edges of the 
model geometry.   
The figure above shows that the fluid flows out from the cavity region, through the tumor 
layer, and into the normal tissue.  The surface plot of pressure and the velocity arrow plot is 
overlaid and shown in Figure 10.  
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Figure 11: Velocity Direction Overlaid on Pressure Surface Plot in the Brain.  It is more clear in the figure that the velocity directionality is 
consistent with the direction of the pressure gradient.  The pressure is highest in the cavity, and lowest on the boundary of the normal tissue, 
causing the fluid to flow outward and away from the wafer layer.   
Figure 11 shows that the direction of the fluid flow is due to the pressure gradient.  
Because the pressure is significantly higher in the cavity region than in the tumor layer and 
normal tissue, the fluid flows outward from the cavity and into these regions. 
The average interstitial fluid velocity in the brain is 6.5 x 10-6 mm/s.  As displayed by the 
pressure surface plot, shown in Figure 9, the pressure gradient in the tumor layer is significantly 
higher than that of the normal tissue and cavity.  This is because there is such a great difference 
in pressures from the cavity to the tumor layer and through the tumor layer into the normal 
tissue.  Additionally, distances further and further into the normal tissue are farther from the high 
pressures associated with the cavity region and therefore farther from the concentration gradient.  
As a result, the pressure in the normal tissue is lower than that of the tumor layer.  Because of 
this, the fluid flows at a higher velocity in the tumor layer, at a value of 4.6 x 10-4 mm/s.  Our 
results also show that the tumor layer has a higher velocity in comparison to both the normal 
tissue and the cavity, with a magnitude difference of 10.  This can be seen in Figures 30 and 31 
in Appendix D.  Figure 30 shows that the velocity in both the cavity and the normal tissue has an 
approximate magnitude of 10-6 mm/s.  This is comparable to the value of 6.5 x 10-6 mm/s found 
in literature.  Figure 31 displays the velocity of the tumor layer and it is shown to be in the order 
of magnitude of 10-5mm/s.  This shows that the pressure in the tumor layer is lower than that of 
the cavity and normal tissue as described in literature and in relation to the surface plot pressure 
gradient.  The correlation of the values found in literature to the values found within our model 
verifies our model as accurate with respect to velocity magnitude.  
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iii.	  Concentration	  
Many clinical trials and experiments have been done to study the penetration of BCNU 
into brain tissue after an implant with the commercially available Gliadel wafers.  We altered our 
model to exclude the nanoparticles in order to show how our model’s parameters compare with 
the in vivo studies done.  Experiments done on rat brains showed that the main transport of drug 
was due to convection and diffusion alone, however when the experiments were done on non-
human primates a different phenomenon was observed.  In the paper by Fleming and Saltzman 
[9], it was explained that the non-human primate studies revealed another transport mechanism 
in addition to convection and diffusion that was not observed in smaller species.  These studies 
noted the presence of BCNU within 1-2cm from the edge of the wafers, on the order of 10-14-10-
13mg/mm3 of tissue for up to 7 days after the implantation.  This result was also observed in the 
studies done by Fung, Ewend, Sills, et al. [26] where significant concentrations of BCNU were 
observed at that distance after a period of time after implantation.  It was hypothesized that the 
other transport mechanism involves BCNU being transferred into cerebrospinal fluid or the 
blood stream and then redepositing into the brain tissue.  
In Fleming and Saltzman’s simulated human brain model, they noticed a peak of BCNU 
around 6 hours, and then a short but sharp decline that was followed by a slower decline over the 
next few days.  Our model showed a similar trend with significant BCNU levels present within 
1.75 cm region past the wafer layer as shown in Figure 13 below.  
 
Figure 12: Concentration of BCNU 1.75cm from the Cavity/Tumor Interface.  There is a sharp peak of BCNU concentration around 8 
hours.  This is followed by a sharp decline in concentration for the subsequent hours.  The plot appears to reach zero at time=15 hours, but in fact 
it reaches zero at hour 20.  It appears to be zero at hour 15 because of the large scale difference between the values for concentration that occur at 
early times vs later times.  The later times have concentrations that are quite a few orders of magnitude different than early times, so the actual 
value are so small in comparison that they appear to be zero. 
According to Figure 12, the BCNU concentration peaks at around 8 hours, and then has a 
sharp decline in the hours after peaking, followed by a slowed decrease.  This is all consistent 
with Fleming and Saltzman’s simulation. The scale on the Figure 12 above does not allow for 
one to see the presence of BCNU at much lower concentrations such as those seen in the 
mentioned studies.  Figure 13 below, shows the graph above for the time 16-24 hours.    
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Figure 13: BCNU Concentration 1.75cm From the Cavity/Tumor Interface.  This figure shows that at times after 15 hours the 
concentration is not yet zero despite appearing as such in Figure 12.  The magnitude of the values is much smaller at these times than the 
magnitude of the values at earlier times, making it difficult to see the presence of concentration after hour 15.   
As Figure 13 shows, the concentration of BCNU is not yet zero, and is still at therapeutic 
levels at this time at 1.75 cm past the wafer in the tissue.  Around hour 21 the concentration is so 
much lower at this point than in other points of the domain that COMSOL has trouble handling 
it. It starts to produce inaccurate values of concentration thus it is unclear the concentrations after 
this point.   
Our model seems to follow the other clinical data, as well as other simulations, of the 
process for the first day, but after the first day the models diverge.  The first rate kinetics of our 
simulation cause the degradation of BCNU, which is a very high rate due to the drug’s half life 
of 31.2 minutes, to eliminate any drug left in the domain by the end of 1 day within the model.  If 
BCNU was taken up by the CSF or blood stream and then were to reenter the tissues, this would 
not be visible in our simulation, and could be the reason for the discrepancy between the in vivo 
studies and our model.  This gives confidence to our model with the inclusion of nanoparticles, 
on the note that the BCNU will potentially be able to linger in the tissue regions surrounding the 
implant for even longer than shown in this simulation.  This means that a therapeutic dose will be 
available in the tissues for longer times than expected, which may lead to a higher effectiveness 
in the use of nanoparticles.   
VI.	  Sensitivity	  Analysis	  	  
i.	  Edema	  Length	  
After the surgery to remove the main tumorous portion of the brain, an edema is likely to 
be produced within the brain tissue surrounding the cavity.  The edema was modeled by having 
the permeability of the vascular network increased to be 100 times the baseline value during the 
time of full edema.  The increased permeability causes increased fluid volume within the normal 
tissue and the remaining tumor tissue, thus causing the pressure in the tissues to reach a constant 
value across the domain.  This then causes the pressure gradient that had formed between the 
cavity and normal tissues to disappear.  Without the pressure gradient, the flow within the tissues 
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slows quite significantly.  This slowing of fluid causes the nanoparticles and drug to move only 
via diffusion, and hence would not be able to move as far as if the pressure gradient had been 
maintained.  The longer the edema is at maximum values, the longer the fluid will be at slowed 
rates.  The longer the fluid is at slowed rates, the less the BCNU is able to travel by convection. 
The less the BCNU is able to travel by convection, the less the BCNU will be able to penetrate 
the tissue.  
 Edema time is considered to be the time spent at maximum values for hydraulic 
conductivity.  The drug is able to reach therapeutic levels for the edema times of 12 hours, 24 
hours, 3 days, and 7 days.  This was determined by finding the point past the wafer at which the 
optimization plot reached zero at the time t=11 days.  The plot shown in Figure 16 below shows 
the curve that the maximum distance of penetration produced for each edema time.   
Since edema length varies from person to person and surgery-to-surgery, it is difficult to 
approximate a person’s edema length to know if the therapeutic levels will be reached at the 4cm 
distance.  The effects caused by the edema during in vivo monkey studies seemed to be resolved 
after 3 days, indicating that the edema was present at maximum values for 1 day, which why that 
value of edema time was used in our model [9]. Figures 14 A and 14 B below show how the 
maximum therapeutic distance reached by the drug was changed for each varying edema time. 
 
Figure 14: (a) Edema Time vs. Distance.  As expected, as the edema time decreases, there is an increase in penetration due to the fact that the 
velocity within the tissue is decreased for a shorter period of time. As the edema time increases, there is a decrease in penetration distance.  For 
he edema time of 264 hours or 11 days, the drug doesn’t reach the maximum goal distance of 4 cm and only is able to reach a distance of 
approximately 3.5 cm.  (b) Figure 15: %Change in Edema vs. Distance.  The percent change in penetration distance of the drug has a decently 
linear relationship with the percent change in edema time.  The R2 value is approximately 0.94, which indicates a good sense of linearity.  This R2 
value could be improved by testing more edema times and plotting more values for the change in penetration distance.   
 As seen in Figure 14a above, as the edema time increases, the maximum therapeutic 
penetration distance decreases.  Figure 14b shows that the percent difference in distance varies 
semi-linearly with the percent change in edema time showing an inverse relationship between the 
variables.  This could help when predicting how far the drug has reached in a patient, after the 
edema time is known.  The maximum distance is still above our target for times 7 days and 
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lower, which is promising news due to the fact that edemas often don’t last past a week’s time.  
This means that majority of patients will receive a therapeutic dose at 4cm. 
ii.	  	  Initial	  Concentration	  of	  Nanoparticles	  in	  the	  Wafers	  
Based on the size of the wafer, an approximation was made as to the amount of 
nanoparticles that could be embedded inside of the wafer. As shown in the calculations in 
Appendix B, there is a range for the radius of the nanoparticle and therefore a maximum amount 
of nanoparticles that could be fit into the wafer. Since the diameter of the nanoparticle is 186 ± 
25 nm, when using the lower limit of 161 nm,	  the approximate number of nanoparticles that 
could fit in all eight wafers is 192x106. When this number is divided by the total volume of all 
eight wafers, the maximum concentration of nanoparticles is 145340 nano/(mm3 wafer).	  	  The 
same process was applied to the rest of the range of total nanoparticles and the differences in the 
distance of BCNU that traveled into the normal tissue at therapeutic levels is shown in Figure 
15a (See Appendix B for range). 
 
Figure 15: (a) Concentration of Nanoparticles vs. Distance. As expected, there was a decrease in the distance traveled, when there was a decrease 
in nanoparticles concentration in the wafers, and an increase in distanced traveled with an increase in concentration of nanoparticles in the wafer. 
The bar in red represents the original value that was tested. When the maximum concentration of nanoparticles in the wafers was tested, there was 
a small increase and when the minimum concentration of nanoparticles in the wafers was tested, there was a small decrease.  Therefore, this was 
not a very significant value to estimate, and our value did not have a great impact on our results. (b) Percent Change in Concentration of 
Nanoparticles vs. Percent Change in Distance. The percent change in penetration distance of the drug has a slightly linear relationship with the 
percent change in concentration nanoparticles in the wafers.  The R2 value is approximately 0.8781, which shows there some correlation with the 
data points. This R2 value could be more realistic with more changes in the parameter value tested.  
As seen in Figure 15a, by increasing the initial concentration by 100%, there was only an 
increase in the distance traveled by 0.95%. Also, when the initial concentration was decreased by 
50%, there was only a decrease in the distance traveled by 1.38%. Therefore, the initial 
concentration of nanoparticles in the wafer does not have a significant effect on the model, and 
the ability of the nanoparticles to deliver BCNU to the brain. Figure 15b shows that the distance 
BCNU traveled does not show a direct correlation to initial concentration of nanoparticles in the 
wafers. Therefore, more values for this parameter should be tested to get a better relationship of 
changes in initial concentration of nanoparticles in the wafer, with difference in distance BCNU 
traveled in the normal tissue at therapeutic levels. 
a	   b	  
20	  
	  
iii.	  	  Initial	  Concentration	  of	  BCNU	  within	  each	  Nanoparticle	  
When changing the radius, another parameter that will be changed would be the initial 
concentration of BCNU within each nanoparticle. Therefore, using the range of total 
nanoparticles, which was used in the sensitivity analysis for initial concentration of 
nanoparticles, the initial concentration of BCNU was calculated (see Appendix B). 
 
Figure 16: (a) BCNU vs. Distance. When changing the total concentration, of BCNU per nanoparticle, an increase in this value caused an 
increase in distance traveled, and a decrease in this value caused a decrease in distance traveled. The bar in red represents the value used in the 
original model. When the maximum BCNU concentration per nanoparticle was tested, there was a small increase and when the minimum BCNU 
concentration per nanoparticle was tested, there was a small decrease. This parameter estimation did not significantly impact our model. (b)  
Percent BCNU vs. Distance. The percent change in penetration distance of the drug has an almost perfect linear relationship with the percent 
change in concentration of BCNU per nanoparticle.  The R2 value is approximately 0.9951, which shows there is a linear correlation with the data 
points.  This R2 value could be more realistic if more values were tested.  
 As shown in Figures 16a, when the maximum concentration of BCNU per nanoparticle 
was used, which was 100% more than the original value there was only an increase of 1.39%. 
When there was a decrease in concentration of BCNU per nanoparticle by 50% there was only a 
decrease in distance traveled by 0.87%. Therefore, this parameter does not have a significant 
effect on the model, and the ability of the nanoparticles to deliver BCNU to the brain. Figure 16b 
shows that the distance BCNU traveled can be roughly estimated, based on change in the total 
concentration of BCNU per nanoparticle. 
iv.	  Diffusivity	  of	  Nanoparticles	  
 The diffusivity of the nanoparticle is based off of the Einstein-Stokes equation as seen in 
Appendix C. However, for this equation, the brain matter was modeled under the assumption that 
the tissue is a viscous fluid. There could be factors that cause this assumption to be incorrect. 
b	  
a	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Figure 17: (a) Diffusivity vs. Distance.  When the diffusivity was decreased by a factor of 10, there was a very small decrease in the distance 
traveled in the normal tissue at therapeutic levels. The red bar indicates the diffusivity used in our model and is multiplied by a constant of 1, so 
there is no change in diffusivity. When the diffusivity was increased by a factor of 10 and 100, there is an increase of distance traveled by 21.55% 
and 116.4% respectively. These values, show that when increasing the diffusivity by factors of 10 show a significant change in results. (b)  
Percent Diffusivity vs. Percent Distance. The percent change in penetration distance of the drug has an almost perfect linear relationship with the 
percent change in diffusivity.  The R2 value is approximately 0.9912, which indicates a good sense of linearity.  This R2 value could be more 
realistic if more diffusivity constant values were tested. 
 As shown in Figures 17a, when the diffusivity of the nanoparticle was decreased by a 
factor of 10, the distance that the BCNU traveled at therapeutic levels only decreased by 0.6%. 
When the diffusivity was increased by a factor of 10 and 100, there was a very steep increase in 
the distance traveled. However, there is no physical reason why the diffusivity would actually 
increase, and so there is no real significant effect when testing realistic diffusivity values. The 
linearity of the percent change in diffusivity versus percent changed in distance traveled can 
show how different polymers with known properties can travel in the brain (Figure 17b). 
VII.	  Conclusions	  	  
 In comparison to the commercially available Gliadel wafers, our delivery method using 
nanoparticles was more efficient. BCNU was present in the tissue at a further distance from the 
cavity edge for longer periods of time.  The BCNU was present in the tissues past our drug goal 
point of 4cm, and even reached to 5.8cm at the appropriate therapeutic concentration for the 
required time period of 2 hours.  BCNU would be able to reach the appropriate distances and 
would be present in the tissue for longer which may lead to increased efficacy of the drug being 
able to treat all the cells in the region rather than just a fraction.  We conclude that our drug 
delivery method would be more efficient than the current method used and would be able to 
prevent recurrence of tumor formation.  
VIII.	  Design	  Recommendations	  
 To enable this model to more realistically portray the modeling of nanoparticle infused 
wafers within the brain, a few additional factors could be included in the model.  One design 
recommendation would be to more accurately model the geometry.  This could be done by 
modeling the brain in 3D.  This would account for diffusion and convection in all 3 dimensions 
and offer more accurate results.  Additionally, individual wafers could be modeled as opposed to 
a	  
b	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the wafer layer as a whole.  This is because the wafer layer doesn’t always form a perfect 
spherical shape and sometimes resembles more of a polygon.  Modeling individual wafers would 
take care of any problems with the geometry of the wafers when described as a whole as well as 
make fluid flow more accurate.  This is because interstitial fluid flow through and around the 
wafers could be more precisely defined when looking at the individual geometry.   
 Next, a design recommendation for the nanoparticles would be the inclusion of diffusion 
through the nanoparticles as well as surface erosion.  Our model currently only shows the surface 
erosion associated with the nanoparticles and the diffusion through them could impact our 
model.  Additionally, a moving mesh could model the surface erosion of the nanoparticles more 
accurately in comparison to the equations that we used and consistent mesh.  The model could 
also be run for the full time period that the BCNU diffuses through the brain (3 weeks).  This 
would provide more information on how the BCNU varies with time. 
Last, another improvement would be to include convection in the cavity (space where the 
tumor was removed).  Once the tumor is removed, the cavity is initially filled up with fluid due 
to the interstitial fluid flow.  Once this reaches steady-state, the convection flow follows a more 
simplified flow pattern.  Our model assumed that the cavity was already at steady-state in order 
to simplify it.  This is not realistic and convection in the tumor cavity should be included for 
accuracy.   
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IX.	  Appendix	  A:	  Model	  Design	  
Governing	  equations:	  
i.	  For	  Diffusion	  of	  Nanoparticles:	  
€ 
∂CNano
∂t + vr
∂CNano
∂r + vz
∂CNano
∂z
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ = DNano
1
r
∂
∂r r
∂CNano
∂r
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ +
∂ 2CNano
∂z2
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟  
ii.	  For	  Diffusion	  of	  BCNU:	  
 
iii.	  For	  Convection	  using	  Brinkman	  Equation:	  
€ 
ρ
ε p
∂u
∂t = ∇ • −ρI +
µ
ε p
∇u + ∇u( )T( ) − 2µ3ε p ∇ • u( )I
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ −
µ
Kbr
+ βF u +Qbr
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ u + F
Qbr = ρ ∇ • u( )
 
	  
Boundary	  Conditions:	  
i.	  For	  Diffusion	  of	  Nanoparticles:	  
 at r = 0mm, due to symmetry 
 at z = 100 mm 
Outflow allowed at z = 0 mm and at r = 100 mm 
 
ii.	  For	  Diffusion	  of	  BCNU:	  
€ 
∂CBCNU
∂r = 0  at r = 0mm, due to symmetry 
 at z = 100 mm 
Outflow allowed at z = 0 mm and at r = 100 mm 
	  
iii.	  For	  Convection:	  
 at r = 0mm, due to symmetry 
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 at z = 100 mm, no slip condition 
Outflow allowed at z = 0 mm and at r = 100 mm 
PbulkTissue = 0.7992 kPa at z = 0 mm and at r = 100 mm 
 
Initial	  Conditions:	  
i.	  For	  Diffusion	  of	  Nanoparticles:	  
CNano, Cavity = 0 nano/mm3 of cavity 
CNano, Wafer = 7.267 x 104 nano/mm3 of wafer 
CNano, TumorTissue = 0 nano/mm3 of tissue 
CNano, NormalTissue = 0 nano/mm3 of tissue 
ii.	  For	  Diffusion	  of	  BCNU:	  
CBCNU, Cavity = 0 mg/mm3 of cavity 
CBCNU, Wafer = 0 mg/mm3 of wafer 
CBCNU, TumorTissue = 0 mg/mm3 of tissue 
CBCNU, NormalTissue = 0 mg/mm3 of tissue 
CBCNU, Nano = 0 mg/mm3 nano 
iii.	  For	  Convection:	  
PTumorTissue = 1.2 kPa 
PNormalTissue = 0.9 kPa 
VCavity = 0 mm/s  
VWafer = 0 mm/s 
VTumorTissue = 0 mm/s 
VNormalTissue = 0 mm/s 
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X.	  Appendix	  B:	  Calculations	  
Nanopartile Degradation Term: 
 
Time (sec) % Volume 
Release 
Volume 
(mm^3) 2928.3 0.00 3.37 x 10-12 
11713.6 18.18 2.76 x 10-12 
17570.3 38.64 2.07 x 10-12 
29283.9 45.00 1.85 x 10-12 
43926.0 52.73 1.59 x 10-12 
90780.2 61.36 1.30 x 10-12 
172775.3 77.73 7.50 x 10-13 
257698.8 85.45 4.90 x 10-13 
427545.5 91.36 2.91 x 10-13 
597392.5 92.27 2.60 x 10-13 
Table values were calculated using information taken from Siepmann and Gopferic.  An 
exponential line was fit to the table values to produce the equation for .  The fitted 
regression line is shown with the best fit equation in Figure 23 below. 
 
Figure 23: The volumetric degradation of the nanoparticle polymer with time. This graph shows how the polymer would decrease in volume as a 
function of the decided radius, releasing BCNU and allowing us to estimate the BCNU generation term as an exponential function with time.  
Drug degradation rate kc:  
t1/2 = 0.52 hours = 1872 sec 
 
Only first order rate kinetics for all domains. [9] 
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Number of nanoparticles in the wafer:  
 
 
 
Approximate that will only fill 4000 nanoparticles in wafer height, and 3000 in wafer area. 
 
 
 
Since the nanoparticles size is 186 ± 25 nm., if all the nanoparticles were to be around 161 nm., this 
is the calculation of how many can fit inside the wafer exactly. A maximum limit to the number of 
nanoparticles that can be placed in the wafer is: 
 
Therefore, the approximation for the maximum amount of nanoparticles that could fit would be 
6000 nanoparticles in the wafer height and 4000 in the wafer area.  
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Size of tumor resurrected estimated by calculating the area that would be covered by 8 Gliadel 
wafers: 
 
 
Number of nanoparticles for sensitivity analysis: 12000000	  (original),	  14625000,	  17500000,	  20625000,	  24000000	  	  
 
Initial concentration of nanoparticles in wafer: 
 
 
 
For the maximum number of nanoparticles: 
	  
 
 
Initial concentration of BCNU in wafer layer for accuracy check model to compare to clinical data 
for Gliadel wafers : 
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Optimization value clow – clinically therapeutic level of BCNU necessary for antitumor 
effectiveness 
 
 
 
Initial concentration of BCNU in wafer layer for no nanoparticle version to approximate cHigh for 
optimization: 
320 mg of BCNU total in wafers was the maximum amount where the side effects were 
consistent with lower amounts of BCNU total in the wafers- maximum threshold for BCNU in 
wafers 
 
320 mg of BCNU total in wafers caused cytotoxic effects and more extreme negative side effects 
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XI.	  Appendix	  C:	  Variables	  
Table 2: Values Used within COMSOL.  The first column gives the name of the value, which describes the meaning of the variable.  The variable 
column gives the variable as it was input and referred to within COMSOL.  The third column gives the value or expression that corresponds to 
the variable listed in the second column.  The source column gives the source from which the value was taken.  
 Name Variable Value/ Expression Source 
Radius of Resurrected 
Tumor 
Rcavity 14.5mm [23] 
Thickness of tumorous 
tissue not removed during 
surgery  
ttumor 3.1mm [23] 
Thickness of wafer layer twafer 1.0mm [21] 
Molecular mass of BCNU MMBCNU 
€ 
214.05g
1mol  
[21] 
Diffusivity of Nanoparticles DNano  
Stokes-Einstein Equation 
Boltzman’s Constant K  Constant 
Temperature T 315.15 K [1] 
Dynamic Viscosity η   [23] 
Interstitial Fluid Density ρ 1000 x 10-9 kg/mm3 [23] 
Volume of Nanoparticle VNano Variable Calculation shown in 
Appendix B. 
Radius of Nanoparticle rNano 
 
Formula for volume of a 
sphere 
Diffusivity of BCNU in 
Cavity 
DBCNU-C  [23]	  
Diffusivity of BCNU in 
Wafer 
DBCNU-W  [23]	  
Diffusivity of BCNU in 
Tumorous Tissue 
DBCNU-T  [23]	  
Diffusivity of BCNU in 
Normal Tissue 
DBCNU-N  [23]	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Half-Life of BCNU t1/2 0.52 hours [1] 
Changing Hydraulic 
Conductivity Parameter 
χ 4.583 x10-3 1/s [23]	  
Hydraulic Conductivity of 
Microvascular wall in 
Tumor Tissue 
*KvT  [23]	  
Hydraulic Conductivity of 
Microvascular wall in 
Normal Tissue 
*KvN  [23]	  
Permeability of the Cavity KBr-C 1 x10-5 mm2 [23]	  
Permeability of the Wafer KBr-W 3.01 x10-7 mm2 [23]	  
Permeability of the Tumor 
Tissue 
KBr-T 6.4x10-8 mm2 [9]	  
Permeability of Normal 
Tissue 
KBr-N 6.4x10-9 mm2 [9]	  
Porosity of Wafer εW 0.45 [23]	  
Porosity of Cavity, Tumor, 
and Normal Tissue 
εC 
εT 
εN 
0.5 [23]	  
Vascular Pressure PV 2.080 kPa [23]	  
Pressure of Bulk Tissue Pbulk 0.7992 kPa [23]	  
Metabolism Rate Parameter Q  [23]	  
Exchange area of blood 
vessels per unit of tumor 
tissue 
S/VT 20 mm [23]	  
Exchange area of blood 
vessels per unit of normal 
tissue 
S/VN 7 mm [23]	  
Osmotic reflection 
coefficient for BCNU in 
σT
T 0.82 [23]	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tumor 
Osmotic reflection 
coefficient for BCNU in 
normal tissues 
σT
N 0.91 [23]	  
Osmotic pressure of plasma 
fluids 
πv
T 
πv
N 
2.660 kPa [23]	  
Osmotic pressure of 
interstitial fluids in tumor 
πi
T 2.000 kPa [23]	  
Osmotic pressure of 
interstitial fluids in normal 
tissues 
πi
N 1.330 kPa [23]	  
Clinically Therapeutic Level 
of BCNU 
clow 25.2 µM [1] 
* - value changes with time.  Supporting table below. 
 
Table 3: Kv values as they change with time.  This term varies based on the time period of the edema and varies based on the location within the 
tumorous tissue or within the normal tissue.  It is a measure of vascular permeability. The tissues take 6 hours to fill will fluid and drain with 
fluid.  During the times of maximum edema, the Kv is 100 times the baseline values.  Baseline values are given in table 2 above.   
 
KvT 2.11x 10-5 0<t<6 hrs 
 2.11x10-5(χt-98.0) 6<t<12 hrs 
 100(2.11x10-5) 12 <t<36 
 2.11x10-5(-χt+694) 36<t<42 
 2.11x10-5 42<t<12 days 
KvN 2.7x10-6 0<t<6 hrs 
 2.7x10-6(χt-98.0) 6<t<12 hrs 
 100(2.7x10-6) 12 <t<36 
 2.7x10-6(-χt+694) 36<t<42 
 2.7x10-6 42<t<12 days 
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XII.	  Appendix	  D:	  Supplementary	  Graphs,	  Tables,	  and	  Figures	  
 
Table 1: Mesh Convergence Trials.  Table 1 shows the concentrations of BCNU at times of 800000 seconds and 900000 seconds that were found 
on point graphs and each run at 2cm into the normal tissue. The number of elements was found through the statistics tab. However, the 
description and max element size determined this number of elements.  
 
 
 
Figure 24: Cavity Pressure from Literature.  The pressure is represented by the solid line and shows an increase in the cavity for the first the 
house.  The pressure is initially at zero and then increases in step-like increments until a value of approximately 1000Pa is reached just after 2 
hours 
.   
Figure 25: Cavity Pressure from Model.  This shows the pressure over a three day time period, in comparison pressures from literature, which are 
in hours.  It is steadily at a pressure of approximately 1.28 kPa for the three hour time period. 
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Figure 26: Tumor Layer Pressure from Literature.  Pressure is modeled by the solid line.  It starts at 1200Pa then rapidly decline to about 
500Pa within the first 0.5 hours.  It then increases in step-like increments until a steady value of 1000Pa is reached around 2.25 hours. 
 
Figure 27: Tumor Layer Pressure from Model.  This models pressure in the tumor layer over 3 days.  In the first 3 hours, a steady line 
around 1.28 kPa is seen. 
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Figure 28: Normal Tissue Pressure From Literature.  The solid line models the pressure in the normal tissue.  It starts at 1000Pa then 
decreases to about 700Pa within the first 30 minutes.  It increases in increments until a pressure of about 900Pa is reached at approximately 
2.25 hours. 
 
Figure 29: Normal Tissue Pressure from Model.  This shows the pressure in the normal tissue over three days.  In the first three hours, the 
pressure is at a constant value of approximately 0.915 kPa. 
 
Figure 30: Velocity for Cavity (blue) and Normal Tissue (red).  The velocity in the cavity remains at consistently low values of about 0.5 x 10-6 
mm/s.  The Normal tissue is initially steady at a value of about 14 x 10-6 mm/s for less than a day and then dips down to down 0.5 x 10-6 mm/s.  
At about day 2 it rises back to the value of 14 x 10-6mm/s. 
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Figure 31: Velocity of Tumor Layer.  The velocity in the tumor layer is initially at a low value and then peaks up to approximately 85 x 10-5mm/s 
after about half a day and remains at this velocity until about 2 days.  Around 2 days it drops back down to this low initial value near zero. 
 
 
Figure 32: Penetration distance Curve.  This figure shows the characteristic curve observed for distances within the normal tissue that were to be 
considered the maximum penetration distance.  The maximum penetration distance was the distance at which this optimization curve was 
observed.  There is a relatively constant value for the optimization for majority of the 12 days, but the distance reaches a therapeutic 
concentration, and hence optimization value, for the first time at day 11. 
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